UY38506A - Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica - Google Patents
Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotroficaInfo
- Publication number
- UY38506A UY38506A UY0001038506A UY38506A UY38506A UY 38506 A UY38506 A UY 38506A UY 0001038506 A UY0001038506 A UY 0001038506A UY 38506 A UY38506 A UY 38506A UY 38506 A UY38506 A UY 38506A
- Authority
- UY
- Uruguay
- Prior art keywords
- lateral sclerosis
- amyotrophic lateral
- treat
- compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se proporcionan pautas posológicas para oligonucleótidos antisentido que se dirigen a SOD1 y sales de estos. Las pautas posológicas se utilizan en el tratamiento de sujetos que tienen o se encuentran en riesgo de desarrollar esclerosis lateral amiotrófica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862779916P | 2018-12-14 | 2018-12-14 | |
US201962807603P | 2019-02-19 | 2019-02-19 | |
US201962840879P | 2019-04-30 | 2019-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38506A true UY38506A (es) | 2020-06-30 |
Family
ID=69160351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038506A UY38506A (es) | 2018-12-14 | 2019-12-11 | Composiciones y metodos para tratar y prevenir la esclerosis lateral amiotrofica |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220073930A1 (es) |
EP (1) | EP3894557A1 (es) |
JP (1) | JP2022513597A (es) |
KR (1) | KR20210131992A (es) |
CN (1) | CN113330116A (es) |
AU (1) | AU2019396522A1 (es) |
BR (1) | BR112021011334A2 (es) |
CA (1) | CA3115549A1 (es) |
CL (1) | CL2021001136A1 (es) |
CO (1) | CO2021008187A2 (es) |
CR (1) | CR20210384A (es) |
IL (1) | IL283833A (es) |
JO (1) | JOP20210143A1 (es) |
MX (1) | MX2021005086A (es) |
PH (1) | PH12021551365A1 (es) |
SG (1) | SG11202103415WA (es) |
TW (1) | TW202035694A (es) |
UY (1) | UY38506A (es) |
WO (1) | WO2020123783A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016040748A1 (en) | 2014-09-12 | 2016-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for detection of smn protein in a subject and treatment of a subject |
BR112020015082A2 (pt) | 2018-01-25 | 2021-01-05 | Biogen Ma, Inc. | Métodos de tratamento da atrofia muscular espinhal |
CN117062911A (zh) * | 2021-03-31 | 2023-11-14 | 渤健马萨诸塞州股份有限公司 | 肌萎缩性脊髓侧索硬化症的治疗 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005504020A (ja) | 2001-07-03 | 2005-02-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | ヌクレアーゼ耐性キメラオリゴヌクレオチド |
WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
ES2890677T3 (es) * | 2014-03-19 | 2022-01-21 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresión de ataxina 2 |
WO2015153800A2 (en) * | 2014-04-01 | 2015-10-08 | Isis Pharmaceuticals, Inc. | Compositions for modulating sod-1 expression |
CN110913866A (zh) * | 2017-05-05 | 2020-03-24 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
WO2018218219A1 (en) * | 2017-05-26 | 2018-11-29 | University Of Miami | Determining onset of amyotrophic lateral sclerosis |
-
2019
- 2019-12-06 TW TW108144617A patent/TW202035694A/zh unknown
- 2019-12-11 UY UY0001038506A patent/UY38506A/es unknown
- 2019-12-12 EP EP19836331.9A patent/EP3894557A1/en active Pending
- 2019-12-12 MX MX2021005086A patent/MX2021005086A/es unknown
- 2019-12-12 KR KR1020217020529A patent/KR20210131992A/ko unknown
- 2019-12-12 SG SG11202103415WA patent/SG11202103415WA/en unknown
- 2019-12-12 JP JP2021525191A patent/JP2022513597A/ja active Pending
- 2019-12-12 AU AU2019396522A patent/AU2019396522A1/en active Pending
- 2019-12-12 US US17/291,199 patent/US20220073930A1/en active Pending
- 2019-12-12 WO PCT/US2019/065936 patent/WO2020123783A1/en unknown
- 2019-12-12 BR BR112021011334-7A patent/BR112021011334A2/pt unknown
- 2019-12-12 CA CA3115549A patent/CA3115549A1/en active Pending
- 2019-12-12 CR CR20210384A patent/CR20210384A/es unknown
- 2019-12-12 JO JOP/2021/0143A patent/JOP20210143A1/ar unknown
- 2019-12-12 CN CN201980080996.2A patent/CN113330116A/zh active Pending
-
2021
- 2021-04-29 CL CL2021001136A patent/CL2021001136A1/es unknown
- 2021-06-09 PH PH12021551365A patent/PH12021551365A1/en unknown
- 2021-06-09 IL IL283833A patent/IL283833A/en unknown
- 2021-06-23 CO CONC2021/0008187A patent/CO2021008187A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202103415WA (en) | 2021-06-29 |
TW202035694A (zh) | 2020-10-01 |
CR20210384A (es) | 2021-12-20 |
CN113330116A (zh) | 2021-08-31 |
MX2021005086A (es) | 2021-08-16 |
BR112021011334A2 (pt) | 2021-09-08 |
CL2021001136A1 (es) | 2022-01-14 |
WO2020123783A1 (en) | 2020-06-18 |
JOP20210143A1 (ar) | 2023-01-30 |
CO2021008187A2 (es) | 2021-09-09 |
US20220073930A1 (en) | 2022-03-10 |
AU2019396522A1 (en) | 2021-05-06 |
JP2022513597A (ja) | 2022-02-09 |
EP3894557A1 (en) | 2021-10-20 |
CA3115549A1 (en) | 2020-06-18 |
KR20210131992A (ko) | 2021-11-03 |
PH12021551365A1 (en) | 2021-11-22 |
IL283833A (en) | 2021-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001136A1 (es) | Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica. | |
CL2019001686A1 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas. | |
BR112017026467A2 (pt) | uso de exossomos para o tratamento de doença | |
CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
BR112018073920A2 (pt) | inibidores de pd-1/pd-l1 para tratamento de câncer". | |
CL2019000935A1 (es) | Composición farmacéutica, métodos para tratamiento y usos de la misma. | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
NI201600021A (es) | Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso | |
BR112018069515A2 (pt) | uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica | |
CO2016000671A1 (es) | Construcciones de variantes de sirp-alfa y sus usos | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017025998A2 (pt) | inibidor de eixo igfbp3/tmem219, composição farmacêutica para uso no tratamento e/ou prevenção de diabetes, método para identificar um indivíduo em risco de desenvolver diabetes tipo 1 e/ou tipo 2 ou para monitorar a resposta a um tratamento terapêutico em um indivíduo e kit | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CO2019002245A2 (es) | Combinación de agonistas de fxr | |
BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
CL2021000930A1 (es) | Piridazinas novedosas | |
AR112291A1 (es) | Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico | |
BR112016026470A8 (pt) | composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto | |
BR112018071972A2 (pt) | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. | |
AR117329A1 (es) | Composiciones y métodos para tratar y prevenir la esclerosis lateral amiotrófica | |
EA201692493A1 (ru) | Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости | |
BR112019008787A2 (pt) | combinações de inibidores de fgfr4 e sequestrantes de ácido biliar | |
EA201990413A1 (ru) | Способ лечения печеночной энцефалопатии | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |